Osteopetrosis via the OSTM1 Gene
Summary and Pricing 
Test Method
Exome Sequencing with CNV Detection
| Test Code | Test Copy Genes | Test CPT Code | Gene CPT Codes Copy CPT Code | Base Price | |
|---|---|---|---|---|---|
| 8791 | OSTM1 | 81479 | 81479,81479 | $990 | Order Options and Pricing |
Pricing Comments
Our favored testing approach is exome based NextGen sequencing with CNV analysis. This will allow cost effective reflexing to PGxome or other exome based tests. However, if full gene Sanger sequencing is desired for STAT turnaround time, insurance, or other reasons, please see link below for Test Code, pricing, and turnaround time information.
An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.
Click here for costs to reflex to whole PGxome (if original test is on PGxome Sequencing platform).
Click here for costs to reflex to whole PGnome (if original test is on PGnome Sequencing platform).
The Sanger Sequencing method for this test is NY State approved.
For Sanger Sequencing click here.Turnaround Time
3 weeks on average for standard orders or 2 weeks on average for STAT orders.
Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.
Targeted Testing
For ordering sequencing of targeted known variants, go to our Targeted Variants page.
Clinical Features and Genetics
Clinical Features
Osteopetrosis (also called Marble bone disease) is a disorder of increased bone density and bone mass caused by malfunction of bone resorption. Affected patients are at high risk of frequent bone fractures, delayed healing, hip osteoarthritis and osteomyelitis. Some patients may have vision loss, hearing loss, and paralysis of facial muscles and bone marrow abnormalities caused by abnormal dense bone structure. Other features include short stature, development delay, dental abnormalities, hepatosplenomegaly, intellectual disability, and epilepsy (Tolar et al. 2004; Del Fattore et al. 2008; Sobacchi et al. 2013). Osteopetrosis is currently known to be caused by mutations in the following genes: CLCN7, LRP5, TCIRG1, TNFSF11, CA2, OSTM1, PLEKHM1, SNX10 and TNFRSF11A.
Genetics
Mutations in OSTM1 can cause autosomal recessive osteopetrosis type 5, which is infantile osteopetrosis with severe central nervous system defects (Pangrazio et al. 2006; Maranda et al. 2008). The OSTM1 protein coded by the OSTM1 gene is a beta subunit of Chloride channel 7 alpha subunit (CLCN7) and may play a role in degradation of G proteins via the ubiquitin-dependent proteasome pathway. To date, less than 10 unique pathogenic variants have been reported. They are: 1 missense, 1 nonsense, 3 splicing, 1 small deletion and 2 gross deletion (Chalhoub et al. 2003; Ott et al. 2013; Human Gene Mutation Database).
Clinical Sensitivity - Sequencing with CNV PGxome
Mutations in OSTM1 were found in 2 out of 160 unrelated, clinically diagnosed, severe osteopetrosis cases (Pangrazio et al. 2006). Two large deletions were found in OSTM1 (Ott et al. 2013).
Testing Strategy
This test provides full coverage of all coding exons of the OSTM1 gene plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define full coverage as >20X NGS reads or Sanger sequencing. PGnome panels typically provide slightly increased coverage over the PGxome equivalent. PGnome sequencing panels have the added benefit of additional analysis and reporting of deep intronic regions (where applicable).
Dependent on the sequencing backbone selected for this testing, discounted reflex testing to any other similar backbone-based test is available (i.e., PGxome panel to whole PGxome; PGnome panel to whole PGnome).
Indications for Test
Candidates for this test are patients with symptoms consistent with autosomal recessive osteopetrosis with central nervous system involvement and the family members of patients who have known OSTM1 mutations. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in OSTM1.
Candidates for this test are patients with symptoms consistent with autosomal recessive osteopetrosis with central nervous system involvement and the family members of patients who have known OSTM1 mutations. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in OSTM1.
Gene
| Official Gene Symbol | OMIM ID |
|---|---|
| OSTM1 | 607649 |
| Inheritance | Abbreviation |
|---|---|
| Autosomal Dominant | AD |
| Autosomal Recessive | AR |
| X-Linked | XL |
| Mitochondrial | MT |
Disease
| Name | Inheritance | OMIM ID |
|---|---|---|
| Osteopetrosis Autosomal Recessive 5 | AR | 259720 |
Related Tests
Citations
- Chalhoub N, Benachenhou N, Rajapurohitam V, Pata M, Ferron M, Frattini A, Villa A, Vacher J. 2003. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nature Medicine 9: 399-406. PubMed ID: 12627228
- Del Fattore A. et al. 2008. Bone. 42: 19-29. PubMed ID: 17936098
- Human Gene Mutation Database (Bio-base).
- Maranda B, Chabot G, Dècarie J-C, Pata M, Azeddine B, Moreau A, Vacher J. 2007. Clinical and Cellular Manifestations of OSTM1-Related Infantile Osteopetrosis. Journal of Bone and Mineral Research 23: 296-300. PubMed ID: 17922613
- Ott C-E, Fischer B, Schröter P, Richter R, Gupta N, Verma N, Kabra M, Mundlos S, Rajab A, Neitzel H, Kornak U. 2013. Severe neuronopathic autosomal recessive osteopetrosis due to homozygous deletions affecting OSTM1. Bone 55: 292-297. PubMed ID: 23685543
- Pangrazio A, Poliani PL, Megarbane A, Lefranc G, Lanino E, Rocco M Di, Rucci F, Lucchini F, Ravanini M, Facchetti F, Abinun M, Vezzoni P, et al. 2006. Mutations in OSTM1 (Grey Lethal) Define a Particularly Severe Form of Autosomal Recessive Osteopetrosis With Neural Involvement. Journal of Bone and Mineral Research 21: 1098-1105. PubMed ID: 16813530
- Sobacchi C, Schulz A, Coxon FP, Villa A, Helfrich MH. 2013. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nature Reviews Endocrinology 9: 522-536. PubMed ID: 23877423
- Tolar J. et al. 2004. New England Journal of Medicine. 351: 2839-49. PubMed ID: 15625335
Ordering/Specimens
Ordering Options
We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
- PGnome sequencing panels can be ordered via the myPrevent portal only at this time.
Requisition Form
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
For Requisition Forms, visit our Forms page
If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.
Specimen Types
Specimen Requirements and Shipping Details
PGxome (Exome) Sequencing Panel
PGnome (Genome) Sequencing Panel
Loading...
×
ORDER OPTIONS
View Ordering Instructions1) Select Test Type
2) Select Additional Test Options
No Additional Test Options are available for this test.